Hebei Senlang Biotechnology Inc., Ltd.
Clinical trials sponsored by Hebei Senlang Biotechnology Inc., Ltd., explained in plain language.
-
Engineered immune cells target tough childhood leukemia in new trial
Disease control Recruiting nowThis phase 2 trial tests an experimental treatment called Senl_B19 CAR-T cells in people aged 3 to 25 whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified to recognize and atta…
Phase: PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated May 17, 2026 02:41 UTC
-
Scientists test personalized cell therapy for stubborn bowel disease
Disease control Recruiting nowThis early study is testing a personalized cell therapy for people with ulcerative colitis that hasn't responded to standard treatments. Doctors will collect immune cells from 12 participants, modify them in a lab to target the disease, and then infuse them back. The main goal is…
Phase: EARLY_PHASE1 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC